EGFR and non-small cell lung carcinoma: Almonertinib is the first innovative third-generation EGFR-TKI in China, which shows stronger inhibitory activities against both T790M mutations and EGFR sensitization while having limited effects on wild-type (WT) EGFR (Cross et al., 2014; Mok et al., 2017; Reungwetwattana et al., 2018; Soria et al., 2018), and it has provided a new option for treating NSCLC patients in China.